The Stop TB Partnership, in collaboration with USAID and its Infectious Disease Detection and Surveillance project (IDDS), have developed packages of customizable training modules for countries to adapt, using the Introducing New Tools Project (iNTP).

To increase screening in hard-to-reach areas, and to help close the TB diagnostic gap in Nigeria, the Stop TB Partnership's Introducing New Tools Project (iNTP) and partners USAID and the Nigeria National TB Program, has been supporting KNCV Nigeria and the Institute of Human Virology, Nigeria (IHVN) in rolling out ultra-portable X-Ray and computer-aided detection technology throughout the country. Watch the video to see the use of this game changing technology in action!

The World Health Organization's Global TB Program and the Special Program for Research and Training in Tropical Diseases are seeking expressions of interest from independent researchers/research groups, academic institutions or other entities with relevant expertise and experience in conducting research on paediatric TB diagnostic approaches.

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Researchers at Tulane University School of Medicine have developed a new highly sensitive blood test for tuberculosis (TB) that screens for DNA fragments of the Mycobacterium tuberculosis bacteria that causes the deadly disease.

RESIST-TB released its May 2022 newsletter with the latest research publications on drug-resistant TB.

Infection by Mycobacterium tuberculosis kills 1.5 million people worldwide every year. Antibiotics to treat TB exist, but in recent years, multi-drug resistant (MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) strains of the bacterium have developed. According to a new study publishing May 31st in the open-access journal PLOS Biology by Ho-Yeon Song of Soonchunhyang University in the Republic of Korea and colleagues, a new class of antibiotics is highly effective against drug-resistant tuberculosis. If validated in clinical trials, the new drug class would represent a major advance in the treatment of tuberculosis.

Community Connect is a valuable addition and important highlight of the Union World Conference on Lung Health 2022 which will take place virtually on 8-11 November 2022. Representatives of the affected community and civil society come together to share experiences and develop solutions on issues surrounding lung health.

A meeting of a subgroup of the World Health Organization (WHO)’s Global Task Force on TB Impact Measurement was held in Geneva, Switzerland on 11-12 May 2022. The meeting focused on an up-to-date review of methods used by WHO to produce TB disease burden estimates. The meeting brought together experts in statistics, modelling and epidemiology from academia, government institutions from high TB burden countries, other technical partners and funding bodies.

Tuberculosis is a stubborn disease, born of yet more stubborn microbes. While many bacterial infections resolve within days of starting antibiotics, tuberculosis often refuses to budge for around six months and, in some cases, may never release its vice grip on the human body. It claimed 1.5 million lives in 2020, second only to COVID-19 among infectious diseases.